The DEA announced an emergency scheduling of Kratom as a Schedule 1 substance, effectively banning the Southeast Asian leaf used by many Americans for pain management and opioid withdrawal. Critics argue the ban was fast-tracked to bypass public comment and protect the interests of pharmaceutical companies developing synthetic versions of Kratom's alkaloids. Reports suggest Kratom has helped users successfully transition off oxycodone, posing a threat to traditional pain medication markets.
